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Results: The extent of the calcific tissue did not change at follow-up (4.084.31% at
baseline vs. 3.414.05% at 6 months and 4.054.05% at 2 years, P0.394) while the
extent of the lipid component decreased (17.578.24% at baseline vs. 8.086.71% at 6
months and 2.693.62% at 2 years, P0.001). The thickness of the overlaying tissue
increased at follow-up in both the lipid cores (by 104m at 6 months and by 157m at
2 years comparing to baseline; P0.001) and calcific spots (by 76m at 6 months and by
105m at 2 years comparing to baseline, P0.001).
Conclusions: It appears that in BRSs the plaque type does not affect neointimal
formation which can cover both lipid and calcific tissues.
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Background: Previous studies have recommended positioning the stent edge at a site of
plaque burden 50%. The aim of this study was to investigate whether targeting less
plaque burden beyond this threshold can further contribute to better lumen preservation at
the stent edge after DES implantation.
Methods: Data were derived from the J-DESsERT trial, a prospective, randomized,
multi-center study, comparing sirolimus- and paclitaxel-eluting stents in de novo native
coronary lesions. IVUS was performed at pre-, post-intervention, and 8-month follow-up.
Volume index (VI: volume/length, mm3/mm) was measured for vessel, lumen, plaque
within the 5-mm reference segments adjacent to the stent edges. % plaque volume (%PV)
was calculated as plaque volume divided by vessel volume. Edge stenosis at follow-up
was defined as the minimum lumen area (MLA) 4 mm2 at the reference segment.
Results: %PV 50% at pre-intervention was achieved in 106 reference segments (61
distal: 45 proximal). Lumen, vessel, and plaque VI, and MLA at pre-intervention were
significantly smaller in the edge stenosis group than the no edge stenosis. However, %PV
was similar between the 2 groups (37.78.1 vs 37.18.2%, respectively, p0.72).
Univariate logistic regression analyses showed no contribution of %PV at pre-intervention
to MLA at follow-up (OR: 0.99, p0.72). These results were consistent, when the distal
and proximal segments were separately analyzed.
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Stenosis
(n33)
No Edge
Stenosis
(n73) p
Pre-intervention
Lumen VI (mm3/mm) 4.8 2.0 8.6 3.1 0.001
Vessel VI (mm3/mm) 7.6 3.4 14.0 5.5 0.001
Plaque VI (mm3/mm) 3.0 1.6 5.4 2.7 0.001
Minimum lumen area (mm2) 4.0 1.7 7.5 2.8 0.001
% Plaque volume (%) 37.7 8.1 37.1 8.2 0.719
Follow-up
Lumen VI (mm3/mm) 4.1 0.9 8.3 2.8 0.001
Vessel VI (mm3/mm) 8.1 2.7 14.5 5.3 0.001
Plaque VI (mm3/mm) 4.0 2.1 6.2 3.2 0.001
Minimum lumen area (mm2) 3.1 0.7 6.9 2.3 0.001
% Plaque volume (%) 47.0 10.1 41.4 9.2 0.006
Conclusions: In lesions with the stent edge positioned at a site of plaque burden50%,
%PV at pre-intervention did not predict stent edge stenosis at follow-up. This result
suggests that aggressive lesion coverage strategy targeting further less plaque burden
beyond 50% as the stent landing zone may not offer additional benefit on lumen
preservation at the stent edge.
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Background: Recent trials using intravascular ultrasound (IVUS) have shown that statin
produces regression and stabilization of coronary artery plaques. The TRUTH study was
a prospective, open-labeled, randomized and multicenter trial to evaluate the effects of
8-month treatment with pitavastatin versus pravastatin on coronary artery plaque com-
position using virtual histology (VH)-IVUS. This study demonstrated that both statins
altered coronary artery plaque composition by significantly decreasing the fibro-fatty
component and increasing the dense-calcium component. However, there are no reports
whether plaque regression or changes in plaque composition using statin could extend
because no study has serially monitored coronary artery plaques for a long-term.
Methods: Among 164 patients who participated in the TRUTH trial, additional IVUS
examination was performed in 39 patients (mean follow-up period 4810 months). IVUS
images qualifying for evaluation at baseline, at 8-month, and at 48-month were obtained
in 30 patients.
Results: Mean age was 679 years and 27 patients (90%) were men. Twenty patients
(67%) were treated with allocated statins without change in the dose at the TRUTH study,
and the dose or type of statin was changed in another 12 patients (40%). Significant
decrease in LDL-C (from 130 to 80 mg/dl, p0.0001) and hs-CRP (from 3690 to 487
ng/ml, p0.001) were observed at 48-month follow-up. HDL-C levels also increased
significantly at 48-month (from 45 to 50 mg/dl, p0.05). Significant decrease in external
elastic membrane volume (-1.1% at 8-month and -5.9% at 48-month) and plaque volume
(-0.5% at 8-month and -3.9% at 48-month) have extended. Furthermore, significant
increase in dense-calcium component (from 0.56 to 0.65 mm3/mm at 8-month and 0.77
mm3/mm at 48-month) and decrease in fibro-fatty component (from 1.09 to 0.94
mm3/mm at 8-month and 0.86 mm3/mm at 48-month) have also extended.
Conclusions: Coronary artery plaque regression and change in plaque composition
associated with statin therapy extend for a long-term. These changes in coronary
atherosclerosis may lead to beneficial effects of statins on long-term clinical outcomes.
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